Register for updates, request contact from a sales rep or MSL, or request medical, reimbursement, or clinical trials information. REQUEST INFORMATION Get reimbursement support and assistance with CORE: Cephalon Oncology Reimbursement Expertise. REIMBURSEMENT Find summaries and links for marketed products including TRISENOX® (arsenic trioxide) PRODUCTS Patients are currently being recruited in the following clinical trials: CEP-701 trials A Randomized, Open Label Study of Oral CEP 701 Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT 3 Activating Mutations. An open label study of oral CEP-701 for the treatment of patients with advanced multiple myeloma. Bendamustine HCl trials A Multi-center Phase II Study of bendamustine HCl in patients with indolent non-Hodgkin's lymphoma (NHL) who are refractory to rituximab. A Phase II Study of bendamustine HCl in combination with rituximab for patients with relapsed indolent NHL. A Multicenter Phase III Study of bendamustine HCl in patients with rituximab-refractory indolent NHL. Information about other ongoing clinical research studies may also be found at www.clinicaltrials.gov. Investigator Sponsored Studies Program Submit your own clinical study proposal to become an investigator with Cephalon Oncology. Learn more at www.CephalonOncologyISSP.com. External Resources Clinical Trials Centerwatch NIH Clinical Trials Listing WebMD In The News  •  Privacy  •  Terms of Use SITE MAP     CONTACT US     CEPHALON.COM ©2008 Cephalon, Inc. All rights reserved. The information presented on this site is intended for U.S. residents only.